GlassScriptPhysician profile
Diane M Daniello
NPI 1841404928
$1,343.23
in general payments reported to CMS, 2019-2025
26 companies · $88.22 in 2025
The $88.22 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $391 · 2022: $497 · 2023: $316 · 2024: $51.38 · 2025: $88.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $229.94 | 2021-2023 | Enhertu |
| Abbvie INC. | $136.13 | 2023-2025 | |
| Amgen INC. | $108.80 | 2021-2023 | Lumakras, Vectibix, Xgeva |
| Astrazeneca Pharmaceuticals LP | $94.35 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $81.94 | 2023 | |
| Emd Serono, INC. | $72.67 | 2022-2023 | Tepmetko |
| Taiho Oncology, INC. | $72.66 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $69.76 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $64.64 | 2022-2023 | Imbruvica, Epkinly |
| Karyopharm Therapeutics INC. | $55.93 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.56 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $48.11 | 2022-2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $29.42 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.71 | 2021-2022 | |
| Eisai INC. | $27.41 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $18.43 | 2024 | |
| Lilly USA, LLC | $17.04 | 2022 | |
| Adaptive Biotechnologies Corporation | $16.93 | 2022 | |
| Pfizer INC. | $15.00 | 2022 | |
| Seagen INC. | $15.00 | 2021 | |
| Janssen Biotech, INC. | $14.51 | 2022 | |
| Deciphera Pharmaceuticals INC. | $14.42 | 2021 | |
| Legend Biotech USA INC. | $14.31 | 2023 | Carvykti |
| Blueprint Medicines Corporation | $13.99 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.89 | 2022 | |
| Glaxosmithkline, LLC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Daniello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.